{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:42Z","timestamp":1760189022101},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Based on findings that thyroxine may have a beneficial effect on the recurrence of Graves' hyperthyroidism, we prospectively studied the effects of a TSH suppressive treatment with thyroxine on the course of Graves' disease in fifty patients with recent onset of hyperthyroidism. After the normalization of serum tri-iodothyronine (T<jats:sub>3<\/jats:sub>) and thyroxine (T<jats:sub>4<\/jats:sub>) concentrations, one group of patients was randomly assigned to a combined treatment with carbimazole and a TSH suppressive dose of T<jats:sub>4<\/jats:sub> for 12 months, followed by another 12 months of TSH suppressive therapy alone. The other group of patients also received carbimazole for one year, but T<jats:sub>4<\/jats:sub> was only added as indicated to normalize elevated TSH serum concentrations, and patients received no therapy during the second year. By the end of the second year, a relapse of hyperthyroidism had occurred in 43% of the patients with and in 45% of the patients without suppressive T<jats:sub>4<\/jats:sub> treatment. In those patients without a relapse of hyperthyroidism, initial thyroid size significantly (<jats:italic>P<\/jats:italic> = 0\u00b701) decreased with time in both treatment groups. However, patients on suppressive T<jats:sub>4<\/jats:sub> treatment tended to have a greater reduction in thyroid volume than patients with normal TSH serum concentrations (<jats:italic>P<\/jats:italic> = 005). In conclusion, we were unable to detect a preventive effect of exogenous TSH suppression on the recurrence of hyperthyroidism. However, our data suggest that TSH suppressive treatment may have a beneficial effect on thyroid enlargement in Graves' disease.<\/jats:p>\n        <jats:p><jats:italic>European Journal of Endocrinology<\/jats:italic> <jats:bold>136<\/jats:bold> 81\u201386<\/jats:p>","DOI":"10.1530\/eje.0.1360081","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T22:12:49Z","timestamp":1229379169000},"page":"81-86","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":21,"title":["Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume"],"prefix":"10.1093","volume":"136","author":[{"given":"Johannes","family":"Pfeilschifter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/136\/1\/eje_136_1_016.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/136\/1\/eje_136_1_016.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:23:12Z","timestamp":1676391792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/136\/1\/81\/6753700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje.0.1360081","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}